How should clinicians counsel patients about clot risk when considering menopausal hormone therapy? We’ll review the data on transdermal vs. oral estrogen, differing progestogens, and risk in special populations. We’ll also cover strategies for shared decision-making and communicating nuanced risk in a clear, supportive way.

We’ll discuss these topics and take your questions in this 60-minute webinar.